During the changeover from analogue to digital screening in the UK, reassurance is needed to confirm that the outcomes with digital are equal to or better than analogue screening. …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.